{
"ranked_hypotheses": [
{
"rank": 1,
"title": "CSF p-tau217 Decline as Treatment Response Threshold",
"mechanism": "Downstream phospho-tau reduction serves as a surrogate marker for therapeutic amyloid clearance and synaptic recovery, with a specific threshold distinguishing responders from non-responders.",
"target_gene": "MAPT",
"confidence_score": 0.7,
"novelty_score": 0.5,
"feasibility_score": 0.8,
"impact_score": 0.9,
"composite_score": 0.71,
"testable_prediction": "Stratify TRAILBLAZER-ALZ 2 participants by CSF p-tau217 percent reduction; those achieving >50% reduction will show statistically significant clinical benefit (CDR-SB change from baseline) enabling a threshold definition for stopping rules.",
"skeptic_concern": "p-tau217 is a downstream consequence of amyloid clearance rather than a driver of recovery; correlation does not establish that targeting this threshold produces clinical benefit independent of amyloid reduction itself."
},
{
"rank": 2,
"title": "PET Amyloid Threshold of 20-25 Centiloids for Clinical Stopping",
"mechanism": "Clinical benefit plateaus at minimal amyloid burden (20-25 Centiloids), with continued treatment yielding diminishing returns beyond this biological threshold.",
"target_gene": null,
"confidence_score": 0.6,
"novelty_score": 0.6,
"feasibility_score": 0.7,
"impact_score": 0.8,
"composite_score": 0.67,
"testable_prediction": "Compare clinical outcomes (CDR-SB, iADRS) between participants who stopped at <25 Centiloids versus those continuing treatment; non-inferiority analysis will establish this as a valid stopping threshold.",
"skeptic_concern": "Individual variability in amyloid-cognition relationships may render a universal threshold clinically inappropriate; regional amyloid patterns and baseline severity could modify the optimal stopping point."
},
{
"rank": 3,
"title": "PSD-95 (DLG4) Synaptic Resilience Recovery Threshold",
"mechanism": "Amyloid clearance to 20-25 Centiloids permits synaptic protein synthesis recovery (DLG4-mediated PSD-95 stabilization), with cognitive recovery non-linear above this threshold.",
"target_gene": "DLG4",
"confidence_score": 0.5,
"novelty_score": 0.7,
"feasibility_score": 0.4,
"impact_score": 0.7,
"composite_score": 0.56,
"testable_prediction": "Measure CSF neurogranin and synaptic PET ligands (synaptic vesicle glycoprotein) at baseline and follow-up; normalize to amyloid centiloid levels to define the synaptic recovery inflection point.",
"skeptic_concern": "PSD-95 is a downstream synaptic protein reflecting neuronal health, not a causal driver of recovery; the molecular pathway connecting extracellular amyloid clearance to postsynaptic protein synthesis remains unspecified."
}
],
"consensus_points": [
"Dose-response relationships exist but specific amyloid threshold values for clinical benefit remain undefined",
"Operationalizing stopping rules requires biomarker-informed thresholds beyond amyloid alone",
"The 20-25 Centiloid range emerged as a potential biological inflection point across multiple perspectives"
],
"dissent_points": [
"Mechanistic hypotheses (PSD-95) are scientifically interesting but lack immediate clinical translation; biomarker-based thresholds (p-tau217) are preferred for near-term practice impact despite being downstream rather than causal"
],
"debate_summary": "While all debaters converged on the critical gap—undefined amyloid thresholds for clinical stopping rules—their prioritization diverged sharply between translational pragmatism (biomarker surrogates with immediate applicability) and mechanistic depth (synaptic protein recovery pathways). The resulting synthesis favors CSF p-tau217 as the most operationally feasible threshold marker, supplemented by direct amyloid PET centiloid targets for practical stopping rules, with PSD-95-mediated synaptic resilience remaining a valuable but longer-term research priority."
}